Modulation of ara-CTP levels by fludarabine and hydroxyurea in leukemic cells

Leukemia

Volumn 15, Issue 1, 2001, Pages 69-73

  Ahlmann, M ^a   Lanvers, C ^a   Lumkemann K ^a   Rossig C ^a   Freund, A ^a   Baumann, M ^a   Boos, J ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Acute leukemia; Cytarabine; Fludarabine; Hydroxyurea; Ribonucleotide reductase inhibitors

Indexed keywords

CYTARABINE; CYTARABINE TRIPHOSPHATE; ENZYME INHIBITOR; FLUDARABINE; HYDROXYUREA; RIBONUCLEOTIDE REDUCTASE;

ACUTE LEUKEMIA; ADULT; ARTICLE; BLAST CELL; CELL LEVEL; CELL STRAIN HL 60; CELL TYPE; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RETENTION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; INCUBATION TIME; LEUKEMIA CELL; LEUKEMIA CELL LINE; LYMPHATIC LEUKEMIA; MODULATION; MYELOID LEUKEMIA; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0035144213     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401992     Document Type: Article

References (39)

1. Effect of dose on the pharmacokinetic and pharmacodynamic effects of cytarabine
2. Biochemical and cellular pharmacology of cytosine arabinoside
3. Induction of topoisomerase I cleavage complexes by 1-beta-D-arabinofuranosylcytosine (ara-C) in vitro and in ara-C-treated cells
4. Intracellular retention of cytosine arabinoside triphosphate in blast cells from children with acute myelogenous and lymphoblastic leukemia
5. Relationships among Ara-CTP pools, formation of (Ara-C)DNA, and cytotoxicity of human leukemic cells
6. Cellular pharmacology and optimal therapeutic concentrations of 1-beta-D-arabinofuranosylcytosine 5′-triphosphate in leukemia blasts during treatment of refractory leukemia with high-dose 1-beta-D-arabinofuranosylcytosine
7. Cytosine arabinoside in childhood leukemia
8. Deoxycytidine kinase: Properties of the enzyme from human leukemic granulocytes
9. Deoxycytidine kinase and deoxycytidine deaminase values correspond closely to clinical response to cytosine arabinoside remission induction therapy in patients with acute myelogenous leukemia
10. Development of resistance to 1-beta-D-arabinofuranosylcytosine after high-dose treatment in childhood lymphoblastic leukemia: Analysis of resistance mechanism in established cells lines
11. An overview of the clinical experience with hydroxyurea
12. Biochemical modulation of arabinosylcytosine for therapy of leukemias
13. Metabolism and action of fludarabine phosphate
14. Fludarabine: Pharmacokinetics, mechanisms of action, and rationales for combination therapies
15. Increased activation of 1-beta-D-arabinofuranosylcytosine by hydroxyurea in L1210 cells
16. Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: Implications for combination therapy
17. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy
18. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias
19. Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: A report from the children's cancer group
20. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia
21. IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: Experiences of a phase II trial
22. Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia
23. FLAG (fludarabine + high-dose cytarabine + G-CSF): An effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias
24. Pharmacology and toxicity of high-dose cytarabine by 72-hour continuous infusion
25. Differential modulation of 1-beta-D-arabinofuranosylcytosine metabolism by hydroxyurea in human leukemic cell lines
26. Transport and metabolism of deoxycytidine and 1-beta-D-arabinofuranosylcytosine into cultured Novikoff rat hepatoma cells, relationship to phosphorylation, and regulation of triphosphate synthesis
27. Biochemical and cytokinetic modulation of L1210 and HL-60 cells by hydroxyurea and effect on 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity
28. Laboratory and clinical studies of biochemical modulation by hydroxyurea
29. Synergisticinteraction between 1-beta-D-arabinofuranosylcytosine, thymidine, and hydroxyurea against human B cells and leukemic blasts in vitro
30. Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia
31. Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes
32. Establishment of a human leukaemic cell line (CMK) with megakaryocytic characteristics from a Down's syndrome patient with acute megakaryoblastic leukaemia
33. Establishment of a leukemic cell model for studying human pre-B to B cell differentiation
34. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia
35. Comparison of hydroxyurea, fludarabine and cladarabine in modulating ara-C pharmacology in the ara-C sensitive and resistant HL-60 and HL-60/Ara-C cell lines
36. Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells
37. A simple isocratic ion-pair high-performance liquid chromatographic determination of 1-beta-D-arabinofuranosylcytosine 5′-triphosphate for intracellular drug-monitoring and in vitro incubation assays
38. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias
39. A cell culture model for the treatment of acute myeloblastic leukemia with fludarabine and cytosine arabinoside